Acquisition and Expansion Plans of Focal Point Healthcare, a CLIA-Authorized Lab for $LBTD;

• Digital Healthcare Company Focused on Covid Testing Services for Important Wide Client Base.
• New Management with Expansive Vision for 2023 and Beyond.
• Nationwide Mobile Covid Testing Services for Business, School, Pre-Flight and Other Key Safety Needs.
• Focused on Acquiring and Developing Companies and Technology that Emphasize a User-Friendly Approach.
• Leadership Team Represents a Unique Blend of Entertainment and Medical Professionals who came out of COVID-19 Testing for TV and Film Productions.
• Subsidiary Focal Point’s Revenue From Medical Testing Exceeds 13 Million for 2021 and 2022.

Lotus Bio-Technology Development Corp. (OTC: LBTD) is committed to improving healthcare and advancing diagnostics through technology development and market acquisition. LBTD currently manages a portfolio of state-of-the-art technologies and innovative companies that are successfully modernizing medicine and prioritizing a user-friendly approach to patient care.

LBTD Subsidiary Focal Point Healthcare offers a nationwide range of mobile Covid Testing which can be sent out within 24 hours of notice.  LBTD has already established multiple locations of operation in California, Arizona, Nevada, and Florida. Current services include the following: 

Drive-Thru Testing

LBTD Drive Thru testing does not require an appointment. LBTD offers two types of tests, a Rapid Antibody test (finger prick) and a PCR (nasal swab).

A licensed clinician performs the Rapid Antibody test (finger prick), and has it interpreted by a LBTD Medical Director. The results will be sent via email to you within 30-45 minutes.

The PCR test (nasal swab) is performed by a licensed clinician and the specimen will be sent to one of the company’s laboratories. Results take 24-48 hours to be sent out via email.

School DistrictsBoard Certified in Pathology Medical Director. On-the-ground, experienced production representative to establish a testing base camp and implement protocols at each studio or location. LBTD Focal Point Health Care owns multiple labs to ensure quick results & fast turn-around to keep productions on time and on budget. LBTD labs and testing services are licensed in all 50 US States & Canada and have been granted Emergency Use Authorization (EAU) by the FDA for SARS-CoV-2 tests.

Preflight Testing

LBTD Focal Point Healthcare Services has partnered with a number of airlines and airports which require preflight Covid testing. By guaranteeing a timely turnaround time, LBTD makes sure that all customers are ready in time for their flights. Results can be sent directly to the customer to bring to the airport.

Corporate Partnerships

LBTD Focal Point Healthcare Services has partnered with a number of businesses, professional sports teams, and facilities. LBTD has streamlined the process on collecting hundreds of samples and getting results in a timely manner. LBTD understands the importance and urgency of administering testing to our corporate accounts to ensure all employees are safe and healthy. LBTD offers flexible dates and times for service. 

With LBTD management having experience and key connections in the entertainment field, the company has been performing important testing services to keep some very high-profile shows running safely and on a timely basis.   

The notable list of entertainment products that LBTD has tested for: 

Netflix

My Unorthodox Life

Bling Empire LA

Bling Empire NYC

Amazon

Tampa Baes

CBS/VIACOM

Bar Rescue

Discovery

Ghost Town

Revolt

Michelle Obama Special

DISCLAIMER:

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for the dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: Lotus Bio-Technology Development Corp.
Contact Person: Hoyt Christopher, CEO
Email: Send Email
Phone: (778) 814-7729
City: Cave Creek
State: Arizona
Country: United States
Website: https://focalpointhealthcare.com/